Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gumarontinib in Advanced MET-altered Solid Tumors
NCT03457532Phase 1Completed
- Sponsor
- Haihe
- Start
- Dec 2017
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glumetinib in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Haihe. Primary endpoints: Dose Limiting Toxicity at 35 days, Maximum Tolerated Dose at 35 days and 2 more. Started Dec 2017; status: completed.
02
Drugs
glumetinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03457532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457532.